Why Investors Shouldn't Be Surprised By Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) 27% Share Price Plunge
H.C. Wainwright Maintains Entrada Therapeutics(TRDA.US) With Buy Rating, Maintains Target Price $20
Express News | HC Wainwright & Co. Reiterates Buy on Entrada Therapeutics, Maintains $20 Price Target
Entrada Therapeutics Analyst Ratings
Entrada Therapeutics Gains Momentum Amid Exon-Skipping Advances and Regulatory Approvals
Roth MKM Maintains Entrada Therapeutics(TRDA.US) With Buy Rating, Maintains Target Price $23
Positive Outlook on Entrada Therapeutics Inc Due to Promising Developments in Duchenne Muscular Dystrophy Treatment
Express News | Entrada Therapeutics Inc - on Track to Initiate Elevate-45-201 Study in Q3 2025
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living With Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping
Entrada Therapeutics, Inc. Just Beat EPS By 55%: Here's What Analysts Think Will Happen Next
Results: Entrada Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Oppenheimer Maintains Entrada Therapeutics(TRDA.US) With Buy Rating, Raises Target Price to $30
Oppenheimer Reaffirms Their Buy Rating on Entrada Therapeutics Inc (TRDA)
Roth MKM Maintains Entrada Therapeutics(TRDA.US) With Buy Rating, Cuts Target Price to $23
Entrada Therapeutics Reports Strong 2024 Financial Results
William Blair Maintains Entrada Therapeutics(TRDA.US) With Buy Rating
Entrada Therapeutics: Regulatory Progress and Strategic Trials Drive Buy Rating
TD Cowen Maintains Entrada Therapeutics(TRDA.US) With Buy Rating
Entrada Therapeutics, Inc. (TRDA) Surpasses Q4 Earnings and Revenue Estimates
Express News | Entrada Therapeutics Expects Csh Runway Into Q2 2027 With $420M In Cash And Equivalents As Of December 31, 2024